Norman E. Lepor, MD, FACC, FAHA, FSCAI - Envisioning the Future of Hyperlipidemia Management: How Can We Leverage PCSK9-Targeting Therapies to Prevent Primary and Secondary Cardiovascular Events?

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Go online to PeerView.com/TVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hyperlipidemia management examines the evidence for PCSK9-targeting therapies to prevent primary and secondary cardiovascular (CV) events. Upon completion of this activity, participants should be better able to: Summarize current clinical evidence and guideline recommendations for the treatment of hyperlipidemia, both for primary and secondary prevention of CV events; Recognize novel mechanisms of action and recent clinical evidence on approved and emerging investigational lipid-lowering therapies that target PCSK9; and Develop treatment protocols using appropriate lipid-lowering therapy including available and emerging agents, alone or in combination, for providing long-term LDL-C reduction and improving adherence.